Crinetics Pharmaceuticals Files 8-K
Ticker: CRNX · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Mar 1, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
Related Tickers: CRNX
TL;DR
CRNX filed an 8-K on Feb 27, 2024, covering material agreements, equity sales, and other events.
AI Summary
On February 27, 2024, Crinetics Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and potential financial events for Crinetics Pharmaceuticals, Inc., requiring investor attention.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and unregistered sales of equity, which can carry inherent risks and require careful review.
Key Numbers
- 001-38583 — SEC File Number (Identifies the company's filing with the SEC.)
- 26-3744114 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- February 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 6055 Lusk Boulevard, San Diego, California 92121 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Crinetics Pharmaceuticals, Inc. enter into?
The filing states that Crinetics Pharmaceuticals, Inc. entered into a 'Material Definitive Agreement' on February 27, 2024, but the specific details of the agreement are not provided in this excerpt.
What is the significance of the 'Unregistered Sales of Equity Securities' mentioned?
This indicates that the company has sold equity securities without registering them with the SEC, which may have implications for investors and regulatory compliance.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 27, 2024.
Where are Crinetics Pharmaceuticals, Inc.'s principal executive offices located?
Crinetics Pharmaceuticals, Inc.'s principal executive offices are located at 6055 Lusk Boulevard, San Diego, California 92121.
What is the company's Standard Industrial Classification (SIC) code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,628 words · 7 min read · ~5 pages · Grade level 13 · Accepted 2024-03-01 16:07:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
Filing Documents
- d773342d8k.htm (8-K) — 37KB
- d773342dex101.htm (EX-10.1) — 274KB
- d773342dex102.htm (EX-10.2) — 199KB
- d773342dex991.htm (EX-99.1) — 10KB
- g773342g0228215350079.jpg (GRAPHIC) — 3KB
- 0001193125-24-055935.txt ( ) — 749KB
- crnx-20240227.xsd (EX-101.SCH) — 3KB
- crnx-20240227_lab.xml (EX-101.LAB) — 17KB
- crnx-20240227_pre.xml (EX-101.PRE) — 11KB
- d773342d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements, including statements relating to the Private Placement, including the filing and timing of a resale registration statement. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties inherent in the Company's business, including the risks and uncertainties described in the Company's periodic filings with the SEC. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing the Company can be found under the heading "Risk Factors" in the Company's periodic reports, including its annual report on Form 10-K for the year ended December 31, 2023. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Securities Purchase Agreement, dated February 27, 2024, by and among Crinetics Pharmaceuticals, Inc. and the persons party thereto. 10.2* Registration Rights Agreement, dated February 27, 2024, by and among Crinetics Pharmaceuticals, Inc. and the persons party thereto. 99.1 Press Release, dated February 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain personal information has been omitted pursuant to Item 601(a)(6) of Regulation S-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: March 1, 2024 By: /s/ R. Scott Struthers, Ph. D. R. Scott Struthers, Ph. D. President and Chief Executive Officer